{
    "id": 24759,
    "fullName": "MTOR L2209V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR L2209V lies within the PI3K/PI4K domain of the Mtor protein (UniProt.org). L2209V results in activation of Mtor downstream signaling and is transforming in cell culture (PMID: 26432419).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6364,
                    "pubMedId": 26432419,
                    "title": "Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432419"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "L2209V",
    "createDate": "07/25/2016",
    "updateDate": "07/25/2016",
    "referenceTranscriptCoordinates": {
        "id": 145311,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11124535G>C",
        "cDna": "c.6625C>G",
        "protein": "p.L2209V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7481,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited foci formation in transformed cells over expressing MTOR L2209V in culture (PMID: 26432419).",
            "molecularProfile": {
                "id": 25512,
                "profileName": "MTOR L2209V"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6364,
                    "pubMedId": 26432419,
                    "title": "Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited Mtor activation in transformed cells over expressing MTOR A1459P in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 25512,
                "profileName": "MTOR L2209V"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apitolisib (GDC-0980) inhibited Mtor activation in transformed cells over expressing MTOR A1459P in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 25512,
                "profileName": "MTOR L2209V"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7450,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited Mtor activation in transformed cells over expressing MTOR L2209V in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 25512,
                "profileName": "MTOR L2209V"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25512,
            "profileName": "MTOR L2209V",
            "profileTreatmentApproaches": [
                {
                    "id": 10433,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR L2209V"
                },
                {
                    "id": 10432,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR L2209V"
                },
                {
                    "id": 10434,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR L2209V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145312,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11124535G>C",
            "cDna": "c.6625C>G",
            "protein": "p.L2209V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145311,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11124535G>C",
            "cDna": "c.6625C>G",
            "protein": "p.L2209V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}